Systematic ReviewSystematic Review
Open Access

Epidemiology of lean/non-obese nonalcoholic fatty liver disease in China

A systematic review and meta-analysis

Jianmei Zhang, Xiaocheng Huang, Luying Dong, Yachao Yang and Dehuan Kong
Saudi Medical Journal September 2023, 44 (9) 848-863; DOI: https://doi.org/10.15537/smj.2023.44.9.20230021

References

  1. 1.↵
    1. Paik JM,
    2. Golabi P,
    3. Younossi Y,
    4. Mishra A,
    5. Younossi ZM.
    Changes in the global burden of chronic liver diseases from 2012-2017: the growing impact of NAFLD. Hepatology 2020; 72: 1605–1616.
    OpenUrl
  2. 2.↵
    1. Long MT,
    2. Noureddin M,
    3. Lim JK.
    AGA clinical practice update: diagnosis and management of nonalcoholic fatty liver disease in lean individuals: expert review. Gastroenterology 2022; 163: 764–774.
    OpenUrlCrossRef
  3. 3.
    1. Papatheodoridi M,
    2. Cholongitas E.
    Diagnosis of non-alcoholic fatty liver disease (NAFLD): current concepts. Curr Pharm Des 2018; 24: 4574–4586.
    OpenUrl
  4. 4.↵
    1. Younes R,
    2. Bugianesi E.
    NASH in lean individuals. Semin Liver Dis 2019; 39: 86–95.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Shi Y,
    2. Wang Q,
    3. Sun Y,
    4. Zhao X,
    5. Kong Y,
    6. Ou X, et al.
    The prevalence of lean/nonobese nonalcoholic fatty liver disease: a systematic review and meta-analysis. J Clin Gastroenterol 2020; 54: 378–387.
    OpenUrlPubMed
  6. 6.
    1. Zou ZY,
    2. Wong VW,
    3. Fan JG.
    Epidemiology of nonalcoholic fatty liver disease in non-obese populations: meta-analytic assessment of its prevalence, genetic, metabolic, and histological profiles. J Dig Dis 2020; 21: 372–384.
    OpenUrl
  7. 7.↵
    1. Lu FB,
    2. Zheng KI,
    3. Rios RS,
    4. Targher G,
    5. Byrne CD,
    6. Zheng MH.
    Global epidemiology of lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Gastroenterol Hepatol 2020; 35: 2041–2050.
    OpenUrlPubMed
  8. 8.↵
    1. Ye Q,
    2. Zou B,
    3. Yeo YH,
    4. Li J,
    5. Huang DQ,
    6. Wu Y, et al.
    Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2020; 5: 739–752.
    OpenUrl
  9. 9.↵
    1. Feldman A,
    2. Wernly B,
    3. Strebinger G,
    4. Eder SK,
    5. Zandanell S,
    6. Niederseer D, et al.
    Liver-related mortality is increased in lean subjects with non- alcoholic fatty liver disease compared to overweight and obese subjects. J Gastrointestin Liver Dis 2021; 30: 366–373.
    OpenUrl
  10. 10.↵
    1. Maier S,
    2. Wieland A,
    3. Cree-Green M,
    4. Nadeau K,
    5. Sullivan S,
    6. Lanaspa MA, et al.
    Lean NAFLD: an underrecognized and challenging disorder in medicine. Rev Endocr Metab Disord 2021; 22: 351–366.
    OpenUrl
  11. 11.↵
    1. Younes R,
    2. Govaere O,
    3. Petta S,
    4. Miele L,
    5. Tiniakos D,
    6. Burt A, et al.
    Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach? Gut 2022; 71: 382–390.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. Zhou F,
    2. Zhou J,
    3. Wang W,
    4. Zhang XJ,
    5. Ji YX,
    6. Zhang P, et al.
    Unexpected rapid increase in the burden of NAFLD in China from 2008 to 2018: a systematic review and meta-analysis. Hepatology 2019; 70: 1119–1133.
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Brooke BS,
    2. Schwartz TA,
    3. Pawlik TM.
    MOOSE reporting guidelines for meta-analyses of observational studies. JAMA Surg 2021; 156: 787–788.
    OpenUrl
  14. 14.↵
    1. Munn Z,
    2. Moola S,
    3. Lisy K,
    4. Riitano D,
    5. Tufanaru C.
    Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and cumulative incidence data. Int J Evid Based Healthc 2015; 13: 147–153.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Lortie CJ,
    2. Filazzola A.
    A contrast of meta and metafor packages for meta-analyses in R. Ecol Evol 2020; 10: 10916–10921.
    OpenUrl
  16. 16.↵
    1. Hunter JP,
    2. Saratzis A,
    3. Sutton AJ,
    4. Boucher RH,
    5. Sayers RD,
    6. Bown MJ.
    In meta-analyses of proportion studies, funnel plots were found to be an inaccurate method of assessing publication bias. J Clin Epidemiol 2014; 67: 897–903.
    OpenUrlCrossRefPubMed
  17. 17.
    1. Zhang YN,
    2. Wang QQ,
    3. Chen YS,
    4. Shen C,
    5. Xu CF.
    Association between serum uric acid to HDL-cholesterol ratio and nonalcoholic fatty liver disease in lean Chinese adults. Int J Endocrinol 2020; 2020: 5953461.
    OpenUrl
  18. 18.
    1. Li C,
    2. Guo P,
    3. Zhang R,
    4. Zhang M,
    5. Li Y,
    6. Huang M, et al.
    Both WHR and FLI as better algorithms for both lean and overweight/obese NAFLD in a Chinese population. J Clin Gastroenterol 2019; 53: e253–e260.
    OpenUrl
  19. 19.
    1. Wang Q,
    2. Shi X,
    3. Wang J,
    4. Zhang J,
    5. Xu C.
    Low serum vitamin D concentrations are associated with obese but not lean NAFLD: a cross-sectional study. Nutr J 2021; 20: 30.
    OpenUrl
  20. 20.
    1. Xu C,
    2. Yu C,
    3. Ma H,
    4. Xu L,
    5. Miao M,
    6. Li Y.
    Prevalence and risk factors for the development of nonalcoholic fatty liver disease in a nonobese Chinese population: the Zhejiang Zhenhai study. Am J Gastroenterol 2013; 108: 1299–1304.
    OpenUrlPubMed
  21. 21.
    1. Wei JL,
    2. Leung JC,
    3. Loong TC,
    4. Wong GL,
    5. Yeung DK,
    6. Chan RS, et al.
    Prevalence and severity of nonalcoholic fatty liver disease in non-obese patients: a population study using proton-magnetic resonance spectroscopy. Am J Gastroenterol 2015; 110: 1306–1314; quiz 1315.
    OpenUrlCrossRefPubMed
  22. 22.
    1. Zeng J,
    2. Yang RX,
    3. Sun C,
    4. Pan Q,
    5. Zhang RN,
    6. Chen GY, et al.
    Prevalence, clinical characteristics, risk factors, and indicators for lean Chinese adults with nonalcoholic fatty liver disease. World J Gastroenterol 2020; 26: 1792–1804.
    OpenUrl
  23. 23.
    1. Zheng X,
    2. Gong L,
    3. Luo R,
    4. Chen H,
    5. Peng B,
    6. Ren W, et al.
    Serum uric acid and non-alcoholic fatty liver disease in non-obesity Chinese adults. Lipids Health Dis 2017; 16: 202.
    OpenUrl
  24. 24.
    1. Luo ZX,
    2. Zeng Q,
    3. Luo R,
    4. Wang Y,
    5. Ge Q.
    Relative contributions of ectopic liver and abdominal fat accumulation to arterial stiffness. Endocr Pract 2015; 21: 574–580.
    OpenUrl
  25. 25.
    1. Wang L,
    2. Guo J,
    3. Lu J.
    Risk factor compositions of nonalcoholic fatty liver disease change with body mass index in males and females. Oncotarget 2016; 7: 35632–35642.
    OpenUrlCrossRef
  26. 26.
    1. Li Y,
    2. Zheng R,
    3. Li J,
    4. Feng S,
    5. Wang L,
    6. Huang Z.
    Association between triglyceride glucose-body mass index and non-alcoholic fatty liver disease in the non-obese Chinese population with normal blood lipid levels: a secondary analysis based on a prospective cohort study. Lipids Health Dis 2020; 19: 229.
    OpenUrl
  27. 27.
    1. Li Q,
    2. Wang N,
    3. Han B,
    4. Chen Y,
    5. Zhu C,
    6. Chen Y, et al.
    Neck circumference as an independent indicator to non-alcoholic fatty liver disease in non-obese men. Nutr Metab (Lond) 2015; 12: 63.
    OpenUrl
  28. 28.
    1. Lu Z,
    2. Ma H,
    3. Xu C,
    4. Shao Z,
    5. Cen C,
    6. Li Y.
    Serum sialic acid level is significantly associated with nonalcoholic fatty liver disease in a nonobese Chinese population: a cross-sectional study. Biomed Res Int 2016; 2016: 5921589.
    OpenUrl
  29. 29.
    1. Lin H,
    2. Wong GL,
    3. Whatling C,
    4. Chan AW,
    5. Leung HH,
    6. Tse CH, et al.
    Association of genetic variations with NAFLD in lean individuals. Liver Int 2022; 42: 149–160.
    OpenUrl
  30. 30.
    1. Wong VW,
    2. Wong GL,
    3. Yeung DK,
    4. Lau TK,
    5. Chan CK,
    6. Chim AM, et al.
    Incidence of non-alcoholic fatty liver disease in Hong Kong: a population study with paired proton-magnetic resonance spectroscopy. J Hepatol 2015; 62: 182–189.
    OpenUrlCrossRefPubMed
  31. 31.
    1. Chen CH,
    2. Huang MH,
    3. Yang JC,
    4. Nien CK,
    5. Yang CC,
    6. Yeh YH, et al.
    Prevalence and risk factors of nonalcoholic fatty liver disease in an adult population of Taiwan: metabolic significance of nonalcoholic fatty liver disease in nonobese adults. J Clin Gastroenterol 2006; 40: 745–752.
    OpenUrlCrossRefPubMed
  32. 32.
    1. Huang JF,
    2. Tsai PC,
    3. Yeh ML,
    4. Huang CF,
    5. Huang CI,
    6. Hsieh MH, et al.
    Risk stratification of non-alcoholic fatty liver disease across body mass index in a community basis. J Formos Med Assoc 2020; 119: 89–96.
    OpenUrl
  33. 33.
    1. Hsu CL,
    2. Wu FZ,
    3. Lin KH,
    4. Chen YH,
    5. Wu PC,
    6. Chen YH, et al.
    Role of fatty liver index and metabolic factors in the prediction of nonalcoholic fatty liver disease in a lean population receiving health checkup. Clin Transl Gastroenterol 2019; 10: 1–8.
    OpenUrl
  34. 34.
    1. You G,
    2. Ding J,
    3. Shen J,
    4. Wang Y,
    5. Sun Y.
    Association between serum ferritin and non-alcoholic fatty liver disease among middle-aged and elderly Chinese with normal weight. Asia Pac J Clin Nutr 2019; 28: 747–753.
    OpenUrl
  35. 35.
    1. Zou Y,
    2. Zhong L,
    3. Hu C,
    4. Sheng G.
    Association between the alanine aminotransferase/aspartate aminotransferase ratio and new-onset non-alcoholic fatty liver disease in a nonobese Chinese population: a population-based longitudinal study. Lipids Health Dis 2020; 19: 245.
    OpenUrl
  36. 36.
    1. Wu L,
    2. Zhang M,
    3. Hu H,
    4. Wan Q.
    Elevated gamma-glutamyl transferase has a non-linear association with incident non-alcoholic fatty liver disease in the non-obese Chinese population: a secondary retrospective study. Lipids Health Dis 2021; 20: 142.
    OpenUrl
  37. 37.
    1. Lu CW,
    2. Lee YC,
    3. Chiang CH,
    4. Chang HH,
    5. Yang WS,
    6. Huang KC.
    Independent dose-response associations between fetuin-A and lean nonalcoholic fatty liver disease. Nutrients 2021; 13: 2928.
    OpenUrl
  38. 38.
    1. Xiao SJ,
    2. Fu GJ,
    3. Lv YL,
    4. Zhong XN,
    5. Wang RH.
    Prevalence and risk factors of fatty liver disease in young and middle-aged population: one center study in Southwestern China. J Gastroenterol Hepatol 2014; 29: 358–364.
    OpenUrl
  39. 39.
    1. Lee SW,
    2. Lee TY,
    3. Yang SS,
    4. Tung CF,
    5. Yeh HZ,
    6. Chang CS.
    Risk factors and metabolic abnormality of patients with non-alcoholic fatty liver disease: either non-obese or obese Chinese population. Hepatobiliary Pancreat Dis Int 2018; 17: 45–48.
    OpenUrl
  40. 40.
    1. Wang Z,
    2. Xu M,
    3. Hu Z,
    4. Hultström M,
    5. Lai E.
    Gender-specific prevalence of fatty liver disease and associated metabolic factors in Wuhan, south central China. Eur J Gastroenterol Hepatol 2014; 26: 1015–1021.
    OpenUrl
  41. 41.
    1. Hu PF,
    2. Zeng X,
    3. Zou ZY,
    4. Tang W,
    5. Guo YB,
    6. Yuan ZL, et al.
    The presence of NAFLD in nonobese subjects increased the risk of metabolic abnormalities than obese subjects without NAFLD: a population-based cross-sectional study. Hepatobiliary Surg Nutr 2021; 10: 811–824.
    OpenUrl
  42. 42.↵
    1. Chen XY,
    2. Wang C,
    3. Huang YZ,
    4. Zhang LL.
    Nonalcoholic fatty liver disease shows significant gender dimorphism. World J Clin Cases 2022; 10: 1457–1472.
    OpenUrl
  43. 43.↵
    1. Honarvar B,
    2. Lankarani KB,
    3. Keshani P,
    4. Rafiee T.
    Dietary determinants of non-alcoholic fatty liver disease in lean and non-lean adult patients: a population-based study in Shiraz, Southern Iran. Hepat Mon 2017; 17: e44962.
    OpenUrl
  44. 44.↵
    1. DiStefano JK.
    NAFLD and NASH in postmenopausal women: implications for diagnosis and treatment. Endocrinology 2020; 161: bqaa134.
    OpenUrl
  45. 45.
    1. Wegermann K,
    2. Garrett ME,
    3. Zheng J,
    4. Coviello A,
    5. Moylan CA,
    6. Abdelmalek MF, et al.
    Gender and menopause modify the effect of single nucleotide polymorphism genotypes on fibrosis in NAFLD. Hepatol Commun 2021; 5: 598–607.
    OpenUrl
  46. 46.↵
    1. Lim HW,
    2. Bernstein DE.
    Risk factors for the development of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis, including genetics. Clin Liver Dis 2018; 22: 39–57.
    OpenUrl
  47. 47.↵
    1. Polyzos SA,
    2. Lambrinoudaki I,
    3. Goulis DG.
    Menopausal hormone therapy in women with dyslipidemia and nonalcoholic fatty liver disease. Hormones (Athens) 2022; 21: 375–381.
    OpenUrl
  48. 48.↵
    1. Chen KL,
    2. Madak-Erdogan Z.
    Estrogens and female liver health. Steroids 2018; 133: 38–43.
    OpenUrlPubMed
  49. 49.↵
    1. Della Torre S.
    Beyond the X factor: relevance of gender hormones in NAFLD pathophysiology. Cells 2021; 10: 2502.
    OpenUrl
  50. 50.↵
    1. Lee C,
    2. Kim J,
    3. Jung Y.
    Potential therapeutic application of estrogen in gender disparity of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Cells 2019; 8: 1259.
    OpenUrlPubMed
  51. 51.↵
    1. Niriella MA,
    2. Kasturiratne A,
    3. Pathmeswaran A,
    4. De Silva ST,
    5. Perera KR,
    6. Subasinghe SKCE, et al.
    Lean non-alcoholic fatty liver disease (lean NAFLD): characteristics, metabolic outcomes and risk factors from a 7-year prospective, community cohort study from Sri Lanka. Hepatol Int 2019; 13: 314–322.
    OpenUrlCrossRefPubMed
  52. 52.↵
    1. Ahadi M,
    2. Molooghi K,
    3. Masoudifar N,
    4. Namdar AB,
    5. Vossoughinia H,
    6. Farzanehfar M.
    A review of non-alcoholic fatty liver disease in non-obese and lean individuals. J Gastroenterol Hepatol 2021; 36: 1497–1507.
    OpenUrl
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section

Keywords